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Abstract
The tyrosine kinase receptor c-kit and its ligand stem cell factor (SCF) have not been explored in prostate cancer
(PC) bone metastasis. Herein, we found that three human PC cell lines and bone marrow stromal cells express a
membrane-bound SCF isoform and release a soluble SCF. Bone marrow stromal cells revealed strong expression
of c-kit, whereas PC cells showed very low levels of the receptor or did not express it all. Using an experimental
model of PC bone metastasis, we found that intraosseous bone tumors formed by otherwise c-kit–negative PC3
cells strongly expressed c-kit, as demonstrated using immunohistochemical and Western blot analyses. Subcuta-
neous PC3 tumors were, however, c-kit–negative. Both bone and subcutaneous PC3 tumors were positive for SCF.
Immunohistochemical analysis of human specimens revealed that the expression frequency of c-kit in epithelial
cells was of 5% in benign prostatic hyperplasia, 14% in primary PC, and 40% in PC bone metastases, suggesting
an overall trend of increased c-kit expression in clinical PC progression. Stem cell factor expression frequency was
more than 80% in all the cases. Our data suggest that the bone microenvironment up-regulates c-kit expression on
PC cells, favoring their intraosseous expansion.
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Introduction
Skeletal metastasis is the biggest cause of morbidity and mortality in
prostate cancer (PC) patients [1]. Once the disease metastasizes,
treatment available at present is palliative and not curative. There-
fore, the identification of new molecular targets is urgently required
for the development of innovative strategies aimed at eliminating or
delaying bone metastases in PC patients.
Overexpression and/or structural alterations of many receptor ty-
rosine kinase (RTK) family members are frequently associated to sev-
eral types of cancers [2], and the activation of RTKs ultimately lead
to an ample spectrum of cellular processes known to be crucial to
cancer growth and progression, such as proliferation, migration, an-
giogenesis, and survival. The proto-oncogene c-kit (CD117, or stem
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cell factor [SCF] receptor) is one of these RTKs and belongs to class III
subfamily, which also includes the platelet-derived growth factor re-
ceptors and the macrophage colony-stimulating factor 1 receptor [3].
c-kit was first identified as the cellular homolog of the oncogene v-kit
present in the genome of Hardy-Zuckerman 4-feline sarcoma virus
[4] and was then found to be allelic with the murine white spot-
ting (W ) locus [5,6]. The ligand for c-kit is the SCF, also known
as mast cell growth factor, kit ligand (KL), or steel factor [7,8]. Alter-
native splicing of the pre-mRNA involving the region corresponding
to exon 6 gives rise to two SCF transcript forms initially expressed at
the cell membrane [9]. The exon 6–containing SCF isoform (SCF248
or KL-1) is a 45-kDa glycoprotein that is readily cleaved and released
from the cell membrane as a soluble SCF (sSCF) of 31 kDa [9,10]
by different proteases [11–13]. Conversely, the SCF isoform lacking
exon 6 (SCF220 or KL-2) is mostly present as a membrane-bound
species of 32 kDa [10]. Both membrane-bound SCF (mSCF) and
sSCF are bioactive [7], although they show different efficiency in ac-
tivating c-kit tyrosine kinase [14]. Activation of c-kit occurs by bind-
ing to noncovalent SCF homodimers, which mediates dimerization
of the receptor followed by autophosphorylation of its intracellular
tyrosine kinase domains, leading to activation of different signaling
transduction pathways [10,15].
From studies in mice with loss-of-function mutations in c-kit and
SCF (W - and Sl-mutants), it was concluded that these factors con-
stitute an important signal transduction system regulating normal cell
growth and differentiation in hematopoiesis, gametogenesis, and me-
lanogenesis [16,17]. Stem cell factor has been found to be expressed
in normal glandular myoepithelium of the breast, bladder and cervi-
cal smooth muscle, and in bone marrow and prostate stromal cells,
whereas the c-kit protein was found on tissue mast cells, basal cells of
skin, hematopoietic stem cells, and glandular breast epithelial cells,
among other cell types [18]. Some malignancies have been reported
to express constitutive gain-of-function mutations in c-kit that in-
duce ligand-independent activation of the receptor [19–22] or muta-
tions that encode for truncated c-kit proteins with still not clear
functions [23,24]. However, other tumor types coexpress c-kit and
SCF [25–29], suggesting the existence of an autocrine loop.
Although previous studies have investigated c-kit and SCF expres-
sion in PC cell lines [30,31], the results reported by the different
groups are to some extent discrepant. Additionally, analyses of hu-
man benign and malignant prostatic tissue have found altered pat-
terns of expression of c-kit and SCF [30], but no studies have
been made in PC bone metastasis. In an attempt to enhance the
knowledge in this area and clarify the disparate results obtained in
other studies, here we investigated the expression of c-kit and SCF
in vitro and in vivo. In addition, an immunohistochemical study in




The human PC cell lines PC3 [32], LNCaP [33], and DU145
[34], derived from metastases to the bone, supraclavicular lymph
node, and brain, respectively, were originally obtained from American
Type Culture Collection (Manassas, VA). Bone marrow stromal
(BMS) cells were obtained by scraping the bone marrow cavity of 22-
to 24-week gestating human male fetal femurs derived from elective
pregnancy terminations in compliance with state and federal regula-
tions (Advanced Bioscience Resources, Alameda, CA). PC3, LNCaP,
and BMS cells were cultured in RPMI-1640 (Invitrogen, Carlsbad,
CA) with 10% fetal bovine serum (FBS; Atlanta Biologicals, Lawrence-
ville, GA). DU145 cells were maintained in DMEM culture medium
(Invitrogen) with 10% FBS. Bone marrow stromal cells displayed a fi-
broblastoid phenotype, as we have previously shown [35].
Real-time Polymerase Chain Reaction
Total RNA was extracted from cultured cells using RNeasy Mini
Kit (Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions. Two micrograms of total RNA were used to synthesize a first-
strand complimentary DNA (cDNA) with an oligo(dT) primer and
Super Script II reverse transcription (Invitrogen). The real-time po-
lymerase chain reaction (PCR) analysis was performed with SYBER
green PCR core reagents (Stratagene, La Jolla, CA) in a Stratagene
Mx4000 cycler, and the data were analyzed using Mx4000 v3.01
software. Fold changes for each gene were normalized to glyceralde-
hyde phosphate dehydrogenase (GAPDH) and then expressed as rel-
ative to gene message expression in BMS cells (arbitrarily set as 1),
according to the 2−ΔΔCT method [36]. The following primers were
used: human SCF, forward (5′-ACT GAC TCT GGA ATC TTT
CTC AGG-3′) and reverse (5′-GAT GTT TTG CCA AGT CAT
TGT TGG-3′); human c-Kit, forward (5′-ATG AGA GGC GCT
CGC GGC GC-3′) and reverse (5′-AGC TTG GCA GGA TCT
CTA AC-3′); and human GAPDH, forward (5′-AAG GTC ATC
CCT GAG CTG AA-3′) and reverse (5′-TGA CAA AGT GGT
CGT TGA GG-3′). For each sample, real-time PCR was performed
in triplicate.
Cell Surface Biotinylation and Immunoblot Analysis
Specific labeling of cell surface proteins was performed using EZ-
Link Sulfo-NHS-Biotin (Pierce, Rockford, IL) according to the
manufacturer’s instructions. Briefly, cells were washed twice with
phosphate-buffered saline (PBS) containing MgCl2 and CaCl2 and
then biotinylated with the Sulfo-NHS-biotin solution. After quench-
ing and washing, cells were lysed in NP-40 lysis buffer (50 mM Tris
pH 7.5, 150 nM NaCl, 1% NP-40) containing a protease inhibitor
cocktail (Roche Applied Science, Indianapolis, IN) and centrifuged at
13,000 rpm. Protein concentrations were measured and normalized
in the obtained supernatants. Biotinylated proteins were precipitated
with NeutrAvidin Protein (Pierce), washed with buffer, separated
on 4% to 12% Bis-Tris gel (Invitrogen), and transferred to a nitro-
cellulose membrane. A monoclonal antibody against the extracellular
N-terminal domain of human c-kit (clone 28, 1:1000; BD Biosci-
ences, Burlington, MA) and a rabbit antibody that cross-reacts with
mouse and human SCF (1:250; Chemicon, Temecula, CA) were
used as primary antibodies. The membranes were then incubated
with 1:2500 antimouse (for c-kit) or 1:4000 goat antirabbit (for
SCF) horseradish peroxidase conjugates (Cell Signaling Technology,
Danvers, MA) at room temperature for 1 hour and then developed
with SuperSignal West Femto Maximum and Pico Chemilumines-
cent substrates (Pierce), respectively. Whole HeLa and CCRF-HSB
cell lysates (Santa Cruz Biotechnology, Santa Cruz, CA) were used as
positive control for SCF and c-kit, respectively. Tissue homogenates
derived from PC3 bone tumors, control human fetal bone xeno-
grafts, or subcutaneous PC3 tumors obtained as described below were
used for Western blot analysis of c-kit and SCF. To confirm the pres-
ence of PC in the tissue extracts, the membranes were stripped and
reprobed with a mixture of anticytokeratin monoclonal antibodies
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(1:500; Sigma Chemical Co., St Louis, MO) that recognize cytoker-
atins 1, 4, 5, 6, 8, 10, 13, 18, and 19. The cytokeratins detected by
these antibodies range in molecular weight (MW) between 40 and
68 kDa. Glyceraldehyde phosphate dehydrogenase (Trevigen, Inc.,
Gaithersburg, MD) was used as a loading control.
Stem Cell Factor ELISA
PC3, LNCaP, DU145, and BMS cells were plated in their respec-
tive complete culture medium in 24-well plates at a concentration of
1 × 105 cells per well. Media were replaced 24 hours later by FBS-
free corresponding culture media supplemented with 0.1% bovine
serum albumin (Sigma Chemical Co.; 500 μl per well). Conditioned
media (CM) were collected 48 hours later, centrifuged to remove cell
debris, and used undiluted to quantitate sSCF using Quantikine
ELISA kit (R&D Systems, Minneapolis, MN) according to the man-
ufacturer’s instructions. Concentrations were calculated using a stan-
dard curve generated with recombinant human SCF included in the
kit and were expressed as picograms per 105 cells per milliliter. The
ELISA assay was performed in triplicate.
Mice
Five-week-old male homozygous C.B-17 scid/scid (severe com-
bined immunodeficient; SCID) mice were purchased from Taconic
Farms (Germantown, NY) and were maintained under aseptic con-
ditions. All procedures involving mice were performed according to
the National Institutes of Health standards established in the Guide-
lines for the Care and Use of Experimental Animals and were ap-
proved by the Animal Investigation Committee at Wayne State
University School of Medicine.
Establishment of PC3 Human Bone Tumors
One fourth human male fetal femurs (Advanced Bioscience Re-
sources) were implanted under the skin of SCID mice as described
previously for the SCID-human model of PC bone metastasis [37].
Four weeks later, 1 × 105 PC3 were injected through the mouse skin
directly into the marrow side of the previously implanted bone. Bone
implants injected with FBS-free culture medium served as controls.
Mice were euthanized 4 weeks later, and the xenografts were har-
vested, fixed in 4% paraformaldehyde, decalcified with 10% ethyl-
enediaminetetraacetic acid (pH 6.5) in PBS, and processed for
immunohistochemistry. Some specimens were used instead to obtain
tissue extracts for Western blot analysis of c-kit and SCF, as described
previously. Briefly, harvested tissues were immediately homogenized
in a mortar (CoorsTek, Golden, CO) with 500 μl of tissue lysis buffer
(150 mM NaCl, 20 mM Tris, pH 7.5, 1% NP-40, and 5 mM
EDTA), the homogenate obtained was centrifuged at 10,000 rpm at
4°C for 10 minutes, and the supernatant was collected and stored at
−80°C for ulterior analysis. Subcutaneous PC3 tumors obtained in
SCID mice and harvested 14 days after tumor inoculation were used
as nonosseous control tumors.
Human Tissue Samples
Clinical samples were obtained from patients between 54 and
78 years of age who underwent radical prostatectomy for primary
PC (n = 21) or transurethral resection for benign prostatic hyperpla-
sia (BPH, n = 22). Forty-three percent of PC specimens had Gleason
scores 5 to 6, whereas the rest had a Gleason score of 7 or higher.
Tissues were fixed in 10% buffered formalin and paraffin-embedded
after surgery. All procedures were performed by the Department of
Urology, Johannes Gutenberg-University, Mainz, Germany. Bone
metastasis tissue samples (n = 20) from rapid autopsies of PC patients
were obtained as previously described [38], in the Department of
Urology, University of Washington, Seattle, WA.
Immunohistochemistry
Five-micrometer tissue sections were deparaffinized, pretreated in
Ag Citrus Plus Retrieval Solution (BioGenex, San Ramon, CA) in a
microwave to achieve antigen retrieval, and incubated for 60 minutes
at room temperature with rabbit antibodies generated against human
SCF (K089; Immuno-Biological Laboratories Co, Japan) or the cy-
toplasmic C-terminal domain of human c-kit (DakoCytomation,
Denmark), both diluted 1:100 in PBS. After incubation, the sections
were washed with PBS and processed using the Vectastain Elite ABC
(peroxidase) kit for rabbit IgG (Vector Laboratories, Burlingame,
CA) according to the manufacturer’s instructions. The specimens
were then incubated with diaminobenzidine (Sigma Chemical
Co.)/H2O2 solution, and cell nuclei were lightly counterstained with
Mayer’s hematoxylin. Negative controls were obtained by replacing
the primary antibodies with nonimmune rabbit immunoglobulin.
Cocultures and Immunomagnetic Cell Separation
Confluent monolayers of BMS cells obtained in six-well plates
were overlaid with PC3 cells (2.5 × 105 cells/well) and cocultured
for 24 hours. The culture medium was then replaced by serum-free
medium, and cocultured cells were harvested 24 and 48 hours later
using 2 mM EDTA. Cell suspensions were incubated with CD326
(antihuman EpCAM) MACS microBeads (Miltenyi Biotec Inc.,
Auburn, CA) and then applied on magnetic columns (MACS Cell
Isolation kit; Miltenyi Biotec) following the manufacturer’s instruc-
tions. Bone marrow stromal and PC3 cells cultured alone were used
as controls. Cell lysates were obtained and analyzed for c-kit using
Western blot as described previously.
Statistical Analysis
Fisher’s exact test was used to assess differences in c-kit and SCF
immunostaining between clinical tumor samples. Statistical analysis
was performed using the GraphPad InStat version 3.0 (GraphPad
Software, San Diego, CA). Differences were considered statistically
significant when P < .05.
Results
SCF and c-kit mRNA Expression in Bone Marrow Stromal
and PC Cells
C-kit and SCF transcript levels of BMS and PC cells were assessed
semiquantitatively by real-time PCR. As can be seen in Figure 1A,
the c-kit mRNA level in BMS cells was three to five times higher
than in PC cells, among which PC3 cells displayed the lowest level.
As for SCF gene expression, DU145 cells showed the highest level.
The mean relative SCF message was around five times lower in BMS
and PC3 cells and 10 times lower in LNCaP cells than in DU145
cells (Figure 1A).
SCF and c-kit Protein Expression and SCF Shedding In Vitro
To determine the protein expression and cell localization of c-kit
and SCF in the different cell lines, we performed cell surface biotin-
ylation followed by Western blot. In agreement with the results
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obtained by real-time PCR, the highest expression of c-kit protein
with a MW of 125 kDa was found in BMS cells. DU145 cells re-
vealed a less intense band with the same MWthan BMS cells, whereas
no expression was evident for LNCaP and PC3 cells (Figure 1B). This
apparent MW of 125 kDa matched with the single band shown by
CCRF-HSB cell lysates used as a positive control (data not shown).
The expression of SCF protein and its localization on the cell sur-
face of the various cell types were verified by immunoblot analysis of
the biotinylated samples pulled down by the avidin beads (Figure 1B).
Stem cell factor was detected as a band of ∼32 kDa, corresponding to
the reported MW of the mSCF isoform lacking exon 6 (SCF220 or
KL-2). Protein and mRNA SCF expression patterns followed the
same trend.
Stem cell factor shedding from the cell surface was verified by anal-
ysis of CM using an enzyme-linked immunoassay. The level of sSCF
released from BMS cells was between 3.8 and 17 times higher than
levels found in CM obtained from the same number of PC cells
(Figure 1C ).
SCF and c-kit in Experimental PC3 Human Bone Tumors
and Clinical Prostatic Tissue Samples
To study c-kit and SCF in PC growing intraosseously, we selected
the PC3 cell line, based on the fact that it was originally established
from skeletal metastasis [32]. Immunohistochemical analysis of PC3
bone tumors generated in the SCID-human model demonstrated
strong positivity for c-kit and SCF. These epitopes were expressed
not only by PC3 cells growing within the bone but also by bone
stromal cells with fibroblast morphology adjacent to tumor cells (Fig-
ure 2, A and B, respectively). Hematopoietic and osteoblast cells
present in control bone xenografts devoid of tumor cells also immu-
nostained positive for c-kit and SCF (Figure 2, C andD, respectively).
Conversely, subcutaneous PC3 tumors, used as a microenvironmental
control, revealed expression of SCF but not of c-kit (Figure 2, E and
F, respectively).
Western blot analysis of tissue homogenates obtained from PC3
bone tumors, and control bone xenografts confirmed the immu-
nohistochemical findings. A 125-kDa protein was detected by the
antibody against c-kit, whereas the anti-SCF antibody detected 35-
and 38-kDa proteins (Figure 3, lanes 1 and 2), which could represent
products with different glycosylation, also found in whole cell lysates
of BMS and PC3 cells grown in vitro (data not shown). The presence
of proteins from tumor cells was confirmed in the lysates using cyto-
keratin immunoblot analysis. Despite the high number of PC3 cells
in the bone tumors (Figure 2, A and B), the intensity of the immu-
noreactive bands obtained for c-kit and SCF was similar to those ob-
tained for the control bone xenografts lysates with an equivalent total
protein content, as evidenced by GAPDH loading (Figure 3, lanes 1
Figure 1. C-kit and SCF mRNA expression in BMS and PC cells, as determined using real-time PCR. Relative quantitation of the SCF and
c-kit genes was performed and normalized by GAPDH gene expression using the 2−ΔΔCT method. Values obtained for PC cells were
then expressed as fold increase/decrease relative to that obtained for BMS cells, which was arbitrarily set as 1 (A). Cell surface expres-
sion of c-kit and SCF was analyzed in avidin-precipitated fractions of biotinylated samples separated on 4% to 12% Bis-Tris minigels
followed by Western blot analysis. Samples were normalized for protein concentrations before precipitation with avidin beads. (B).
Soluble SCF was quantitated in CM using ELISA, and the results were expressed as mean ± SE for triplicate determinations (C).
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and 2). This suggests that the tumor cells contributed to c-kit and
SCF production in the bone tumors. In the case of c-kit, the results
were unexpected because we predicted that the absence of c-kit pro-
tein in PC3 cells, as revealed in vitro, would have diluted the levels of
c-kit derived from bone tissue in the homogenates of PC3 bone
tumors. In addition, Western blot analysis of tissue homogenates ob-
tained from subcutaneous PC3 tumors revealed SCF expression but
nondetectable c-kit (Figure 3, lane 3), displaying an expression pat-
tern similar to that observed in vitro. Taken together, these results
suggest an induction of c-kit in PC3 cells by the bone microenviron-
ment. To investigate this phenomenon, we cocultured PC3 and BMS
cells for 24 hours and then separated them by immunomagnetic en-
richment using microbeads bound to an antibody against EpCAM, a
cell adhesion molecule constitutively expressed by epithelial cells
[39]. Cell lysates derived from both cell populations were analyzed
by immunoblot analysis using antibodies against c-kit. No c-kit ex-
pression was detected in either PC3 cells cultured alone or together
with BMS following immunomagnetic separation, whereas the level
of c-kit expression on BMS cells was found to be the same in both
fractions (data not shown). We should acknowledge, however, that
the conditions found in vivo when PC3 interact with the bone mi-
croenvironment may not be replicated in the coculture performed
and/or that cells other than BMS could induce c-kit expression in
the PC cells.
To determine whether the c-kit and SCF expression patterns dis-
played by the experimental bone metastasis model were similar to
those present in human bone metastasis, we performed an immuno-
histochemical analysis of autopsy specimens from PC patients. We
also analyzed archival samples of BPH and primary prostate adeno-
carcinoma, aimed to evaluate the different specimens under the same
methodological procedures and to compare our results with others
obtained in previous studies. We found c-kit expression in epithelial
cells in only 5% and 14% of patients with BPH and primary PC,
respectively, whereas c-kit was positive in 40% of patients with bone
metastasis (Table 1 and Figure 4). C-kit expression was not detected
in primary prostate PCs with Gleason score lower than 7, and only
25% of the tumors with higher Gleason score showed c-kit positivity
in the epithelial compartment (P > .05). In contrast, positive SCF
expression was observed in the glandular epithelium of 95% of
BPH and primary PC samples studied and in 85% of patients with
Figure 2. Immunohistochemical staining of c-kit (A) and SCF (B) in bone tumors obtained by injection of PC3 cells into human bone
xenografts in SCID mice. The immunostaining for c-kit (C) and SCF (D) in control human fetal bone xenografts show reactivity in osteo-
blasts and hematopoietic cells. Subcutaneous PC3 tumors used as controls were also immunostained for c-kit (E) and SCF (F).BT indicates
bone trabeculae; yellow arrow, stromal cells; black arrowhead, osteoblasts; black arrow, hematopoietic cells. Scale bars, 50 μm.
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bone metastasis. Positive immunostaining for SCF was also noticed
in blood vessels found in primary carcinomas and bone metastasis.
Discussion
Prostate cancer is the second leading cause of cancer-related death
and the most common cancer in males. Approximately 65% to 75%
of PCs metastasize to the bone marrow where SCF expressed by stro-
mal cells interacts with c-kit expressed on the surface of progenitor
cells [11]. In addition, different tumors have been shown to express
SCF and/or c-kit [25–29]. Therefore, in tumors that metastasize to
bone, such is the case of PC, autocrine, juxtacrine, and/or paracrine
Figure 4. Immunohistochemical staining of c-kit and SCF in representative serial paraffin sections of human specimens. Note that the
strongest immunostaining for c-kit and SCF is restricted to the epithelial cells. A diffuse cytoplasmic immunoreactivity for c-kit and SCF
was consistently displayed by fibromuscular stromal cells (arrowhead) in BPH samples. Blood vessels (arrow) occasionally immuno-
stained positive for SCF in primary prostate carcinomas and bone metastasis. BT indicates bone trabeculae. Scale bars, 50 μm.
Figure 3.Western blot analysis for c-kit and SCF in tissue homoge-
nates obtained from PC3 tumor growing within a human bone
xenograft (lane 1), control human bone xenograft injected with cul-
turemedium (lane 2), and PC3 subcutaneous tumor (lane 3). Glycer-
aldehyde phosphate dehydrogenase was used as loading control.
Human cytokeratin was used as an epithelial marker to detect PC3
cells in the lysates.
Table 1. Expression of c-Kit and SCF in Benign andMalignant Prostate Tumors and BoneMetastasis.
Tissue Expressing c-kit (%) Expressing SCF (%) Total
BPH 1 (5) 21 (95) 22
Primary PC 3 (14) 20 (95) 21
Bone Metastasis 8 (40)* 17 (85) 20
*P = .0077 between BPH and bone metastasis (Fisher’s exact test).
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mechanisms could act in concert favoring intraosseous tumor expan-
sion directly or indirectly.
This study examines for the first time the status of c-kit and SCF
in PC bone metastasis, both in an experimental model and in pa-
tient’s specimens. The expression of c-kit has been previously inves-
tigated in PC cell lines [30,31], although with conflicting results. In
accordance with Savarese et al. [31], we identified c-kit mRNA tran-
scripts in LNCaP, PC3, and DU145 cells, which showed lower levels
than in BMS cells. However, as opposed to their findings using im-
munocytochemical techniques in those PC cells [31], our Western
blot analysis of surface biotinylated samples only found c-kit protein
expressed on the cell membrane of DU145 cells (we also analyzed
BMS cells, which revealed higher c-kit protein levels than DU-145
cells). The discrepancy between their results and ours at the protein
level could be due not only to the different techniques used but also
to the region of c-kit recognized by the antibodies used. We used an
antibody generated against the extracellular domain of c-kit, which
allows determining the expression of the receptor present on the cell
surface susceptible of binding to SCF. The use of antibodies that rec-
ognize other domains of the receptor could account for the detection
of other c-kit proteins only present in the cytoplasm, which could
even be catalytically inactive. That is the case of a truncated c-kit pro-
tein, which contains part of the interkinase domain, the phosphotrans-
ferase domain, and the C-terminal region of the receptor, but lacks the
ATP binding site, and that is found to be expressed in the cytoplasm of
LNCaP cells but not in PC3 cells [24].
Our data regarding SCF release from the different PC cells to the
extracellular milieu are mostly in agreement with those previously re-
ported for the same cells [31], with significantly lower levels of sSCF
than BMS cells. In addition, we found that only the mSCF isoform
lacking exon 6 (SCF220 or KL-2) is expressed on the surface of the
different cells in relative levels that match those observed for relative
SCF message. Our results are in agreement with previous studies in
which it has been demonstrated that the half-life of KL-2 at the cell
surface is 10-fold or higher than that of KL-1 [9,40]. This suggests
that most of the sSCF found in the CM of the cells derive from the
larger splice form KL-1. Because both mSCF and sSCF are biolog-
ically active [7,41], it is probable that the membrane-bound KL-2
binds in a juxtacrine manner to c-kit receptors expressed by neigh-
boring cells, whereas the soluble form of KL-1 acts in autocrine and/
or paracrine manner/s. In addition, it is likely that binding of mSCF
and sSCF to c-kit might affect different cell mechanisms, given their
capacity to induce a more or less persistent activation of the receptor
and probable differences in downstream cell signaling [41]. More-
over, the interaction between PC cells and different resident cells
in the bone microenvironment would result in a complex network
of interactions between SCF and c-kit of different sources that, ulti-
mately, could disrupt the local homeostasis and affect the expansion
of metastatic PC deposits within the bone.
The c-kit and SCF protein expression profiles observed by us in vitro
initially suggested that PC cells would be able to contribute SCF to
the bone microenvironment but would not be responsive to juxtacrine
(mSCF) or autocrine/paracrine (sSCF) stimulation, because they lack
the c-kit receptor or they express it at very low levels. Surprisingly, we
found that c-kit was strongly expressed by PC3 bone tumors, but not
by PC3 subcutaneous tumors, suggesting that the bone microenviron-
ment up-regulates c-kit expression in PC3 cells. Therefore, it is reason-
able to assume that PC3 cells become responsive to SCF produced by
different resident cells present within the bone and further contrib-
uted by the PC3 cells themselves. The potential functional signifi-
cance of this induced c-kit protein expression may prove challenging
because PC3 cells do not show detectable levels of c-kit on the cell
surface in vitro. Therefore, the use of PC3 cells with ectopic expres-
sion of c-kit may be necessary to mimic the in vivo up-regulation of
c-kit shown by PC3 cells within the bone microenvironment.
Our immunohistochemical analysis of human specimens revealed
an increased incidence in c-kit expression in the epithelial compart-
ment of PC bone metastasis, compared to BPH and primary PC,
strengthening the data found by us in the SCID-human model
and suggesting the relevance of PC-associated c-kit to bone metasta-
sis. As opposed to our study and that of Di Lorenzo et al. [42], Simak
et al. [30] reported a higher frequency of c-kit expression in epithelial
cells in BPH than in primary PC. This difference could be due to dif-
ferent techniques used in the studies. As for SCF, we found that
most BPH, primary PC, and PC bone metastasis specimens expressed
it in the epithelial compartment. Our results reveal an association be-
tween coexpression of SCF and c-kit in PC cells and bone metastasis,
suggesting that both ligand and receptor should be expressed by PC
cells for intraosseous development and therefore indicating the exis-
tence of an autocrine loop. However, paracrine and juxtacrine mech-
anisms exerted by tumor-derived and bone-derived SCF cannot be
excluded and deserve to be investigated in future studies.
The increased frequency of c-kit shown by PC skeletal metastasis
could be the result of a selective dissemination and/or growth into
the bone of c-kit–positive cells already present in PC primary tumors,
which are known to be heterogeneous [43]. These c-kit–positive cells
could also be “stem-like” cancer cells [44,45], which were reported to
be present in some human metastatic lesions [46]. However, our data
obtained with the experimental bone metastasis model suggest an
up-regulation of PC c-kit expression by the bone microenvironment.
On the basis of our findings, we propose that the SCF/c-kit axis
may contribute to the pathophysiology underlying PC skeletal metas-
tasis. Further studies on signaling pathways and cell functions trig-
gered by the activation of c-kit expressed by PC cells are needed to
clarify the role and therapeutic value of this RTK and its ligand in PC
bone metastasis.
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